CN115210241A - 咪唑并吡嗪化合物枸橼酸盐固体形态 - Google Patents
咪唑并吡嗪化合物枸橼酸盐固体形态 Download PDFInfo
- Publication number
- CN115210241A CN115210241A CN202180006273.5A CN202180006273A CN115210241A CN 115210241 A CN115210241 A CN 115210241A CN 202180006273 A CN202180006273 A CN 202180006273A CN 115210241 A CN115210241 A CN 115210241A
- Authority
- CN
- China
- Prior art keywords
- compound
- degrees
- citrate
- solid form
- citrate salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
提供用作BTK抑制剂的化合物(I)的枸橼酸盐固体形态，特别是晶型I和晶型II及其制备方法以及在制备治疗疾病的药物中的应用。
Description
PCT国内申请，说明书已公开。
Claims (25)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020101562073 | 2020-03-09 | ||
| CN202010156207 | 2020-03-09 | ||
| PCT/CN2021/079211 WO2021179996A1 (zh) | 2020-03-09 | 2021-03-05 | 咪唑并吡嗪化合物枸橼酸盐固体形态 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115210241A true CN115210241A (zh) | 2022-10-18 |
| CN115210241B CN115210241B (zh) | 2023-09-08 |
Family
ID=77672315
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180006273.5A Active CN115210241B (zh) | 2020-03-09 | 2021-03-05 | 咪唑并吡嗪化合物枸橼酸盐固体形态 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN115210241B (zh) |
| WO (1) | WO2021179996A1 (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115702898A (zh) * | 2021-08-04 | 2023-02-17 | 成都倍特药业股份有限公司 | 一种btk抑制剂固体制剂及其制备方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106831787A (zh) * | 2017-01-20 | 2017-06-13 | 成都倍特药业有限公司 | 用作布鲁顿酪氨酸激酶抑制剂的化合物及其制备方法和应用 |
| CN112142762A (zh) * | 2019-06-27 | 2020-12-29 | 成都倍特药业股份有限公司 | 一种布鲁顿酪氨酸激酶抑制剂的晶体及其制备方法和用途 |
-
2021
- 2021-03-05 CN CN202180006273.5A patent/CN115210241B/zh active Active
- 2021-03-05 WO PCT/CN2021/079211 patent/WO2021179996A1/zh active Application Filing
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106831787A (zh) * | 2017-01-20 | 2017-06-13 | 成都倍特药业有限公司 | 用作布鲁顿酪氨酸激酶抑制剂的化合物及其制备方法和应用 |
| CN112142762A (zh) * | 2019-06-27 | 2020-12-29 | 成都倍特药业股份有限公司 | 一种布鲁顿酪氨酸激酶抑制剂的晶体及其制备方法和用途 |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115702898A (zh) * | 2021-08-04 | 2023-02-17 | 成都倍特药业股份有限公司 | 一种btk抑制剂固体制剂及其制备方法 |
| CN115702898B (zh) * | 2021-08-04 | 2024-02-09 | 成都倍特药业股份有限公司 | 一种btk抑制剂固体制剂及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115210241B (zh) | 2023-09-08 |
| WO2021179996A1 (zh) | 2021-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110092775B (zh) | 靶向cdk4/6激酶抑制剂的晶型 | |
| CN110041326B (zh) | 盐酸小檗碱与反丁烯二酸共晶物及制备方法和其组合物与用途 | |
| CN115210241B (zh) | 咪唑并吡嗪化合物枸橼酸盐固体形态 | |
| KR102531772B1 (ko) | Cdk4/6 키나아제 억제제를 타겟팅하는 결정형 | |
| WO2017101777A1 (zh) | 吡咯并嘧啶化合物的盐 | |
| WO2021143954A2 (zh) | 一种氟伐替尼或其甲磺酸盐的晶型及其制备方法 | |
| WO2021047528A1 (zh) | 一个烟醇醚衍生物的马来酸盐及其晶型和应用 | |
| CN110520425B (zh) | EOC315 Mod.I晶型化合物及其制备方法 | |
| EP3653603A1 (en) | Fenlean (flz) crystal g form, preparation method, and composition and use thereof | |
| JP2022517396A (ja) | Ｅｇｆｒ阻害剤の塩、結晶形及びその製造方法 | |
| CN105753869B (zh) | 一种cdk抑制剂和mek抑制剂的共晶及其制备方法 | |
| CN112010905B (zh) | 甲磺酸帕拉德福韦晶型及其应用 | |
| AU2015392050B2 (en) | Fumarate of pyridylamine compound and crystals thereof | |
| CN111718258A (zh) | 蓓萨罗丁与聚乙烯吡咯烷酮共无定型物及制备方法和其组合物与用途 | |
| WO2023006057A1 (zh) | 氨基吡唑并嘧啶化合物的晶体 | |
| CN109400604B (zh) | 2,3,4,9-四氢-1H-吡啶并[3,4-b]吲哚类化合物及用途 | |
| CN112759583B (zh) | 包含呋喃基的喹啉类衍生物及其制备方法和用途 | |
| CN117466898A (zh) | 氨基吡唑并嘧啶化合物的晶体 | |
| KR20230152118A (ko) | 약물 조성물 및 이의 제조 방법 및 용도 | |
| Trivedi et al. | Nintedanib as the First Treatment for Group of Progressive Interstitial Lung Diseases: A Review of Patent Literature | |
| CN116410133A (zh) | 一种氟伐替尼氢溴酸盐及其制备方法 | |
| CN117924291A (zh) | 咪唑并吡嗪衍生物的晶型及其制备方法和应用 | |
| CN117776908A (zh) | 异阿魏酸半哌嗪盐及其制备方法和药物组合物与用途 | |
| CN103570616B (zh) | N′‑直链烷酰基邻吡啶酰肼衍生物及其制法和药物组合物与用途 | |
| EA042455B1 (ru) | Кристаллическая форма ингибитора, нацеленного на киназу cdk4/6 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |